Literature DB >> 17684617

[Endogenous Cushing's syndrome: clinical and laboratorial features in 73 cases].

Lucio Vilar1, Luciana A Naves, Maria da Conceição Freitas, Eliane Moura, Viviane Canadas, Edmundo Leal, Luciano Teixeira, Amaro Gusmão, Vera Santos, Renata Campos, Marise Lima, Renata Paiva, José Luciano Albuquerque, Célia S Egito, Carlos A Botelho, Ruy Lyra, Monalisa F Azevedo, Luiz Augusto Casulari.   

Abstract

We studied clinical and laboratorial features of 73 patients with endogenous Cushing's syndrome, subdivided as follows: 46 (63%) with Cushing's disease (CD), 21 (28.7%) with an adrenal tumor and 6 (8.2%) with ectopic ACTH secretion (EAS). The rate of typical manifestations of hypercortisolism was similar regardless its etiology. In 100% of cases of Cushing's syndrome we observed serum cortisol levels greater than 1.8 microg/dL in low-dose dexamethasone (DMS) suppression tests, as well as elevation of serum or salivary midnight cortisol. However, urinary free cortisol was normal in 11.5% of patients. ACTH levels were suppressed in patients with adrenal tumors, normal or high in CD and always high in EAS. In the 8-mg overnight DMS suppression test, serum cortisol suppression > 50% was observed in 78.2% of cases of CD and in 33.3% of subjects with EAS, while an 80% suppression was only seen in CD. After stimulation with CRH or DDAVP an ACTH increase > 35% occurred in 81% of individuals with CD and 16.6% of those with EAS, while an ACTH increase > 50 achieved 100% specificity. Moreover, the combination of serum cortisol suppression > 50% and an ACTH increase > 35% in both tests only occurred in Cushing's disease. Pituitary magnetic resonance imaging identified 100% of macroadenomas and 59.4% of microadenomas in patients with CD. Among 10 patients that underwent bilateral inferior petrosal sinus sampling, a central-to-peripheral ACTH gradient > 3 after CRH or DDAVP had 90% sensitivity and 100% specificity for Cushing's disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17684617     DOI: 10.1590/s0004-27302007000400010

Source DB:  PubMed          Journal:  Arq Bras Endocrinol Metabol        ISSN: 0004-2730


  4 in total

1.  Long Term Follow-up after Endoscopic Endonasal Approach for the Treatment of Cushing's Disease.

Authors:  Alexandre Bossi Todeschini; Américo Rubens Leite Dos Santos; Ricardo Landini Lutaif Dolci; José Viana Lima Junior; Nilza Maria Scalissi; Paulo Roberto Lazarini
Journal:  J Neurol Surg B Skull Base       Date:  2018-09-20

Review 2.  The ectopic ACTH syndrome.

Authors:  Krystallenia I Alexandraki; Ashley B Grossman
Journal:  Rev Endocr Metab Disord       Date:  2010-06       Impact factor: 6.514

3.  Cushing's Syndrome Due to CRH and ACTH Co-secreting Pancreatic Tumor--Presentation of a New Case Focusing on Diagnostic Pitfalls.

Authors:  Athanasios Fountas; Zoe Giotaki; Nikos Ligkros; Efthymia D Tsakiridou; Stelios Tigas; Wolfgang Saeger; Agathocles Tsatsoulis
Journal:  Endocr Pathol       Date:  2015-09       Impact factor: 3.943

4.  The Role of Isotretinoin Therapy for Cushing's Disease: Results of a Prospective Study.

Authors:  Lucio Vilar; José Luciano Albuquerque; Ruy Lyra; Erik Trovão Diniz; Frederico Rangel Filho; Patrícia Gadelha; Ana Carolina Thé; George Robson Ibiapina; Barbara Sales Gomes; Vera Santos; Maíra Melo da Fonseca; Karoline Frasão Viana; Isis Gabriella Lopes; Douglas Araújo; Luciana Naves
Journal:  Int J Endocrinol       Date:  2016-02-29       Impact factor: 3.257

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.